News

As part of the $55.5m deal, Samsung BioLogics will manufacture Tildrakizumab, which is an investigational IL-23p19 inhibitor that is being assessed for the treatment of moderate to severe plaque

Under the deal, Exscientia will combine its artificial intelligence (AI) knowledge with the expertise of GSK to discover novel and selective small molecules for up to 10 disease-related

“We are excited to be bringing Triptodur, a new treatment option for children impacted by the disruptive effects of CPP, to the U.S. market,” said Ed Schutter, President

This indication includes treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor ALL. Adults with Ph+ relapsed

The company has reported top-line results from Neucourse phase 3 clinical trial in patients with post-herpetic neuralgia and Alday phase 3 clinical trials in patients with fibromyalgia. Mirogabalin

Upon commencement of the GLP toxicology study, CytomX will receive a $15 million milestone payment from AbbVie as part of the 2016 strategic oncology collaboration between the companies.

The aim is to obtain more efficient products for patients. “Allogenic cell therapies using CAR-T open a major field of innovation in the treatment of cancer,” stated Patrick

Dubbed SAVOIR, the phase 3 trial will be held globally in five to ten countries to assess the efficacy and safety of savolitinib in comparison with sunitinib. The open-label,

The approval has been followed by a recommendation of the Committee for Medicinal Products for Human Use (CHMP) in May. It allows to market the drug in the